Drug Profile
Research programme: anticancer therapeutic antibodies - Merck Serono/MorphoSys
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Merck Serono; MorphoSys
- Class Monoclonal antibodies
- Mechanism of Action Checkpoint kinase inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Cancer in Germany
- 12 Jun 2014 Early research in Cancer in Germany (unspecified route)